Hydromer, Inc. (HYDI.OB – OTCBB; HDO - BSX), a New Jersey biotech company, is addressing the issue of late thrombosis and potential restenosis in stents by announcing an evaluation phase of a new polymeric entity (F200) which exhibits significant retardation of smooth aortic muscle cell mitosis without the use of active drug components.
